Dr. Reddy’s (NYSE: RDY) details GST tax demands and penalties

Rhea-AI Filing Summary

Dr. Reddy’s Laboratories Limited has received three orders from the GST Authority covering FY 2019-20 to FY 2021-22, raising tax demands with interest and penalties on the ground that certain supplies are taxable in nature.

The penalties total ₹2,19,48,944 for FY 2019-20, ₹50,406 for FY 2020-21, and ₹4,384 for FY 2021-22. The company states that, based on its evaluation, these orders have no material impact on its financials, operations, or other activities and it will evaluate filing an appeal with the appellate authority.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

March, 2026

Commission File Number 1-15182

DR. REDDY’S LABORATORIES LIMITED

(Translation of registrant’s name into English)

8-2-337, Road No. 3, Banjara Hills

Hyderabad, Telangana 500 034, India

+91-40-49002900

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F x                                 Form 40-F ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ______

Note:  Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ______

Note:  Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  ¨                                No   x

If “Yes” is marked, indicate below the file number assigned to registrant in connection with Rule 12g3-2(b): 82-________.

EXHIBITS

Exhibit Number		Description of Exhibits
99.1		Intimation dated March 17, 2026

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	DR. REDDY’S LABORATORIES LIMITED (Registrant)
Date: March 17, 2026	By:	/s/ K Randhir Singh
		Name: K Randhir Singh
		Title:   Company Secretary

3

Exhibit 99.1

Dr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills Hyderabad – 500 034, Telangana, India CIN: L85195TG1984PLC004507 Tel:       + 91 40 4900 2900 Fax:     + 91 40 4900 2999 Email: mail@drreddys.com Web:   www.drreddys.com

March 17, 2026

National Stock Exchange of India Ltd. (Scrip Code: DRREDDY)

BSE Limited (Scrip Code: 500124)

New York Stock Exchange Inc. (Stock Code: RDY)

NSE IFSC Ltd. (Stock Code: DRREDDY)

Dear Sir/Madam,

Ref: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

This is to inform that the Company has received three separate orders from GST Authority towards tax demand including interest and penalty for the period FY 2019-20 to FY 2021-22. The details as required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 are as hereunder:

Name of the authority	:	Commercial Taxes Department – Office of the Joint Commissioner (ST), Chennai Intelligence -II.
Nature and details of the action(s) taken, or order(s) passed	:	The Company has received order seeking demand including interest and penalty under section 74 of the TNGST Act, 2017.
Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority	:	Orders dated March 16, 2026, were received by the Company on March 16, 2026.
Details of the violation(s)/ contravention(s) committed or alleged to be committed	:	The authority has passed the orders primarily on the ground that certain supplies are taxable in nature.
Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible	:	The above orders levy penalty as detailed below:
			Financial Year	Penalty
			FY 2019-20	2,19,48,944/-
			FY 2020-21	50,406/-
			FY 2021-22	4,384/-
		Based on our evaluation, there is no material impact on the financials, operations, or other activities of the Company.

The Company will evaluate filing necessary appeal with the appellate authority in this regard.

This is for your information and records.

Yours faithfully,

For Dr. Reddy’s Laboratories Limited

K Randhir Singh

Company Secretary, Compliance Officer & Head-CSR

FAQ

What GST orders has Dr. Reddy’s Laboratories (RDY) received for FY 2019-20 to FY 2021-22?

Dr. Reddy’s Laboratories received three separate GST Authority orders covering FY 2019-20 to FY 2021-22. These orders raise tax demands with interest and penalties, primarily asserting that certain supplies made by the company are taxable in nature under applicable GST provisions.

What is the total GST penalty amount disclosed by Dr. Reddy’s Laboratories (RDY)?

The company reports penalties of ₹2,19,48,944 for FY 2019-20, ₹50,406 for FY 2020-21, and ₹4,384 for FY 2021-22. These amounts arise from GST Authority orders under section 74 of the TNGST Act, 2017 from the Commercial Taxes Department.

Which authority issued the GST tax demand orders to Dr. Reddy’s Laboratories (RDY)?

The orders were issued by the Commercial Taxes Department – Office of the Joint Commissioner (ST), Chennai Intelligence-II. They were passed under section 74 of the TNGST Act, 2017 and relate to the taxability of certain supplies made by the company during FY 2019-20 to FY 2021-22.

When did Dr. Reddy’s Laboratories (RDY) receive the GST orders and for which period?

The company received the GST orders on March 16, 2026. These orders cover financial years 2019-20, 2020-21, and 2021-22, addressing tax demands including interest and penalties related to supplies the authority considers taxable under the relevant GST law.

What impact do the GST penalties have on Dr. Reddy’s Laboratories’ (RDY) financials and operations?

Dr. Reddy’s states that, based on its evaluation, the GST orders have no material impact on its financials, operations, or other activities. While penalties are quantified for each year, the company characterizes their overall impact on its business as not material.

How does Dr. Reddy’s Laboratories (RDY) plan to respond to the GST tax demand orders?

The company indicates it will evaluate filing an appeal with the appellate authority against the GST orders. This suggests Dr. Reddy’s is considering legal recourse while maintaining that the current financial and operational impact of these tax demands is not material.

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 RDY0860_EX99-1 52.4 KB